Article
Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study.
Clinical and experimental immunology - 1 Feb 2009
Thrower S L, James L, Hall W, Green K M, Arif S, Allen J S, Van-Krinks C, Lozanoska-Ochser B, Marquesini L, Brown S, Wong F S, Dayan C M, Peakman M
Abstract excerpt
Immunotherapeutic strategies under consideration for type 1 diabetes include modification of the autoimmune response through antigen-specific routes. Administration of short peptides representing T cell epitopes targeted by patients with the disease represents one approach. This study evaluated safety and mechanistic outcomes during first-in-man intradermal administration of a human leucocyte antigen-DR4...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.